CHMP recommends Rebif use in patients with early signs of MS
This article was originally published in Scrip
Executive Summary
Experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) are recommending that the terms of the European market authorisation of Rebif (interferon beta-1a) should be amended to treat patients with early signs of multiple sclerosis. The CHMP is recommending that 44 micrograms of Rebif three times weekly should be given to patients who have experienced a single demyelinating event, an early sign of multiple sclerosis, and who are at high risk of developing the disease.